 | • レポートコード：MRC2303H234 • 出版社/出版日：360iResearch / 2022年10月11日 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、2021年に259.3億ドルであった世界の血栓症治療薬市場規模が2022年に273.8億ドルとなり、今後は年平均5.73％成長して2027年までに362.5億ドルに達すると予測しています。当書は、血栓症治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤分類別（第Xa因子阻害剤、ヘパリン、P2Y12血小板阻害剤）分析、疾患別（心房細動、深部静脈血栓症、肺塞栓症）分析、流通チャネル別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめております。なお、当書には、Aspen Pharmacare Holdings Limited、AstraZeneca PLC、AuroMedics Pharma LLC、Baxter International, Inc.、Bayer AG、Biogen Inc、Boehringer Ingelheim GmbH、Bristol-Myers Squibb、DAIICHI SANKYO COMPANY, LIMITED.、GlaxoSmithKline plcなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の血栓症治療薬市場規模：薬剤分類別 - 第Xa因子阻害剤の市場規模 - ヘパリンの市場規模 - P2Y12血小板阻害剤の市場規模 ・世界の血栓症治療薬市場規模：疾患別 - 心房細動における市場規模 - 深部静脈血栓症における市場規模 - 肺塞栓症における市場規模 ・世界の血栓症治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の血栓症治療薬市場規模：地域別 - 南北アメリカの血栓症治療薬市場規模 アメリカの血栓症治療薬市場規模 カナダの血栓症治療薬市場規模 ブラジルの血栓症治療薬市場規模 ... - アジア太平洋の血栓症治療薬市場規模 日本の血栓症治療薬市場規模 中国の血栓症治療薬市場規模 インドの血栓症治療薬市場規模 韓国の血栓症治療薬市場規模 台湾の血栓症治療薬市場規模 ... - ヨーロッパ/中東/アフリカの血栓症治療薬市場規模 イギリスの血栓症治療薬市場規模 ドイツの血栓症治療薬市場規模 フランスの血栓症治療薬市場規模 ロシアの血栓症治療薬市場規模 ... - その他地域の血栓症治療薬市場規模 ・競争状況 ・企業情報 |
The Global Thrombosis Drug Market size was estimated at USD 25.93 billion in 2021 and expected to reach USD 27.38 billion in 2022, and is projected to grow at a CAGR 5.73% to reach USD 36.25 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Thrombosis Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the market was studied across Factor Xa Inhibitor, Heparin, and P2Y12 Platelet Inhibitor.
Based on Disease Type, the market was studied across Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism.
Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Thrombosis Drug market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Thrombosis Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Thrombosis Drug Market, including Aspen Pharmacare Holdings Limited, AstraZeneca PLC, AuroMedics Pharma LLC, Baxter International, Inc., Bayer AG, Biogen Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, DAIICHI SANKYO COMPANY, LIMITED., GlaxoSmithKline plc, GoodRx, Inc., Grifols, S.A, Inari Medical, Inc., ITALFARMACO S.p.A, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Mylan N.V., Pfizer, Inc, Sanofi, and Vasudha Pharma.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Thrombosis Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Thrombosis Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Thrombosis Drug Market?
4. What is the competitive strategic window for opportunities in the Global Thrombosis Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Thrombosis Drug Market?
6. What is the market share of the leading vendors in the Global Thrombosis Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Thrombosis Drug Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Poor eating habits and sedentary lifestyle among consumers
5.1.1.2. Rising cases of cardiovascular diseases
5.1.1.3. Increasing geriatric and obese population
5.1.1.4. Recent advances in hematology
5.1.2. Restraints
5.1.2.1. Side effects risk associated with thrombosis drugs
5.1.3. Opportunities
5.1.3.1. Government awareness programs and support for healthcare improvements
5.1.3.2. Advanced therapeutic strategies for thrombosis
5.1.4. Challenges
5.1.4.1. Limited awareness regarding thromboembolism conditions
5.2. Cumulative Impact of COVID-19
6. Thrombosis Drug Market, by Drug Class
6.1. Introduction
6.2. Factor Xa Inhibitor
6.3. Heparin
6.4. P2Y12 Platelet Inhibitor
7. Thrombosis Drug Market, by Disease Type
7.1. Introduction
7.2. Atrial Fibrillation
7.3. Deep Vein Thrombosis
7.4. Pulmonary Embolism
8. Thrombosis Drug Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Thrombosis Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Thrombosis Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Thrombosis Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Aspen Pharmacare Holdings Limited
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AuroMedics Pharma LLC
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Baxter International, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bayer AG
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Biogen Inc
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Boehringer Ingelheim GmbH
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Bristol-Myers Squibb
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. DAIICHI SANKYO COMPANY, LIMITED.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. GlaxoSmithKline plc
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. GoodRx, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Grifols, S.A
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Inari Medical, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. ITALFARMACO S.p.A
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Janssen Pharmaceuticals, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Johnson & Johnson
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Mylan N.V.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Pfizer, Inc
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sanofi
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Vasudha Pharma
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing